WO2026120558 - MACROCYCLIC COMPOUNDS AS ATM INHIBITORS
National phase entry is expected:
Publication Number
WO/2026/120558
Publication Date
11.06.2026
International Application No.
PCT/IB2025/062490
International Filing Date
05.12.2025
Title **
[English]
MACROCYCLIC COMPOUNDS AS ATM INHIBITORS
[French]
COMPOSÉS MACROCYCLIQUES EN TANT QU'INHIBITEURS DE L'ATM
Applicants **
SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
Inventors
KARCHE, Navnath P.
CHIMANWALA, Sabbirhusen Y.
BHUNIYA, Debnath
PALLE, Venkata P.
Priority Data
202421096506
06.12.2024
IN
202521066597
12.07.2025
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3798 | |
| EPO | Filing, Examination, Granting | 23231 | |
| Japan | Filing, Examination, Granting | 2803 | |
| South Korea | Filing, Examination, Granting | 3424 | |
| USA | Filing, Examination, Granting | 14840 |
Total:
48,096
Contact Us
Abstract[English]
The present disclosure relates to macrocyclic compounds as potent Ataxia-Telangiectasia Mutated (ATM) inhibitors, their tautomers, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates, isotopes, prodrugs and N-oxides. The present disclosure also relates to the processes for their preparation, their compositions, their combination with suitable medicament and their use for the treatment of diseases modulated by ATM kinase.[French]
La présente divulgation concerne des composés macrocycliques en tant que puissants inhibiteurs de l'Ataxia-Telangiectasia Mutated (ATM), leurs tautomères, stéréoisomères, sels pharmaceutiquement acceptables, hydrates, solvates, isotopes, promédicaments et N-oxydes. La présente divulgation concerne également les procédés de préparation de ces composés, leurs compositions, leur combinaison avec un médicament approprié et leur utilisation pour le traitement de maladies modulées par la kinase ATM.